stoxline Quote Chart Rank Option Currency Glossary
  
ANI Pharmaceuticals, Inc. (ANIP)
58.92  -0.27 (-0.46%)    02-14 16:00
Open: 59
High: 59.416
Volume: 125,883
  
Pre. Close: 59.19
Low: 58.1464
Market Cap: 1,238(M)
Technical analysis
2025-02-14 4:46:16 PM
Short term     
Mid term     
Targets 6-month :  71.62 1-year :  83.65
Resists First :  61.31 Second :  71.62
Pivot price 59.42
Supports First :  56.01 Second :  52.74
MAs MA(5) :  59.44 MA(20) :  59.18
MA(100) :  57.61 MA(250) :  61.18
MACD MACD :  0.7 Signal :  0.8
%K %D K(14,3) :  51.4 D(3) :  57.4
RSI RSI(14): 52.8
52-week High :  70.8 Low :  52.5
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ANIP ] has closed above bottom band by 31.9%. Bollinger Bands are 52.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 59.48 - 59.97 59.97 - 60.29
Low: 57.14 - 57.67 57.67 - 58.03
Close: 58.21 - 59.05 59.05 - 59.61
Company Description

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Headline News

Mon, 17 Feb 2025
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now? - Yahoo Finance

Mon, 17 Feb 2025
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? - Yahoo Finance

Wed, 12 Feb 2025
abrdn plc Makes New $13.16 Million Investment in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - MarketBeat

Tue, 11 Feb 2025
ANI Pharmaceuticals: More Than Just A Generics Company (NASDAQ:ANIP) - Seeking Alpha

Fri, 31 Jan 2025
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Fri, 31 Jan 2025
Is ANI Pharmaceuticals (ANIP) Stock Undervalued Right Now? - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers - Specialty & Generic
Shares Out 21 (M)
Shares Float 16 (M)
Held by Insiders 10.5 (%)
Held by Institutions 101.1 (%)
Shares Short 2,290 (K)
Shares Short P.Month 2,350 (K)
Stock Financials
EPS -0.47
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 20.73
Profit Margin -1.3 %
Operating Margin -7.4 %
Return on Assets (ttm) 1.2 %
Return on Equity (ttm) -1.7 %
Qtrly Rev. Growth 12.5 %
Gross Profit (p.s.) 15.79
Sales Per Share 26.42
EBITDA (p.s.) 3.9
Qtrly Earnings Growth 0 %
Operating Cash Flow 93 (M)
Levered Free Cash Flow 50 (M)
Stock Valuations
PE Ratio -125.37
PEG Ratio 0
Price to Book value 2.84
Price to Sales 2.22
Price to Cash Flow 13.33
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android